Profile data is unavailable for this security.
About the company
Voyager Therapeutics, Inc. is a biotechnology company focused on advancing neurogenetic medicines. The Company’s pipeline includes programs for Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple other diseases of the central nervous system. Many of its programs are derived from its TRACER AAV capsid discovery platform, which is used to generate novel capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Its pipeline of programs, all of which are in preclinical development, include Anti-Tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy Program, Tau Silencing Gene Therapy Program, Vectorized Anti-Amyloid Antibody Early Research Program, Friedreich’s Ataxia Program: VY-FXN01, GBA1 Gene Replacement Program, HD Program, and others. VY-TAU01 is for the treatment of Alzheimer’s disease. SOD1 Silencing Gene Therapy Program is for the treatment of ALS.
- Revenue in USD (TTM)250.01m
- Net income in USD132.33m
- Incorporated2013
- Employees162.00
- LocationVoyager Therapeutics Inc75 Hayden AvenueLEXINGTON 02421United StatesUSA
- Phone+1 (857) 259-5340
- Fax+1 (302) 655-5049
- Websitehttps://www.voyagertherapeutics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cartesian Therapeutics Inc | 26.00m | -219.71m | 455.58m | 38.00 | -- | -- | -- | 17.52 | -41.77 | -41.77 | 5.03 | -25.87 | 0.1104 | -- | 4.17 | 684,315.80 | -93.31 | -43.66 | -116.36 | -66.84 | -- | -- | -844.91 | -136.35 | -- | -0.5814 | -- | -- | -76.53 | 95.83 | -721.02 | -- | -25.27 | -- |
| Theravance Biopharma Inc | 57.42m | -55.19m | 459.38m | 99.00 | -- | 2.14 | -- | 8.00 | -0.9704 | -0.9704 | 1.04 | 4.43 | 0.1161 | -- | 3.35 | 580,040.40 | -11.16 | -40.51 | -11.79 | -48.50 | -- | -- | -96.11 | -305.27 | -- | -- | 0.00 | -- | 11.84 | -0.9956 | 40.54 | -- | -19.24 | -- |
| PepGen Inc | 0.00 | -78.63m | 459.94m | 64.00 | -- | 3.12 | -- | -- | -3.30 | -3.30 | 0.00 | 4.55 | 0.00 | -- | -- | 0.00 | -43.62 | -- | -48.51 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -13.78 | -- | -- | -- |
| Fate Therapeutics Inc | 63.53m | -160.93m | 462.10m | 181.00 | -- | 1.09 | -- | 7.27 | -1.63 | -1.63 | 0.6456 | 3.74 | 0.1049 | -- | 3.15 | 351,011.10 | -26.56 | -31.82 | -30.40 | -36.05 | -- | -- | -253.30 | -359.33 | -- | -- | 0.00 | -- | -34.03 | 68.05 | 42.88 | -- | 21.72 | -- |
| C4 Therapeutics Inc | 20.76m | -132.49m | 462.37m | 145.00 | -- | 1.66 | -- | 22.28 | -2.67 | -2.67 | 0.4181 | 4.07 | 0.0514 | -- | 3.13 | 143,144.80 | -32.82 | -25.91 | -36.80 | -29.45 | -- | -- | -638.34 | -292.35 | -- | -- | 0.00 | -- | -33.25 | 1.40 | -3.37 | -- | -8.68 | -- |
| Editas Medicine Inc | 78.12m | -153.22m | 466.27m | 265.00 | -- | 1.33 | -- | 5.97 | -2.06 | -2.06 | 1.03 | 4.27 | 0.1542 | -- | 10.19 | 294,803.80 | -30.24 | -29.85 | -34.43 | -33.19 | -- | -- | -196.13 | -347.71 | -- | -- | 0.00 | -- | 296.32 | 19.59 | 30.49 | -- | -0.1477 | -- |
| Neurogene Inc | 0.00 | -36.32m | 471.27m | 91.00 | -- | 2.53 | -- | -- | -29.21 | -29.21 | 0.00 | 14.51 | 0.00 | -- | -- | 0.00 | -21.46 | -32.70 | -23.85 | -34.73 | -- | -- | -- | -- | -- | -- | 0.0006 | -- | -- | -- | 36.90 | -- | 45.63 | -- |
| Third Harmonic Bio Inc | 0.00 | -30.82m | 476.36m | 30.00 | -- | 1.74 | -- | -- | -0.9461 | -0.9461 | 0.00 | 6.71 | 0.00 | -- | -- | 0.00 | -10.70 | -- | -10.91 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 12.32 | -- | -- | -- |
| Travere Therapeutics Inc | 145.24m | -376.33m | 476.44m | 380.00 | -- | 2.35 | -- | 3.28 | -4.98 | -1.50 | 1.96 | 2.66 | 0.1988 | 1.40 | 7.68 | 382,205.30 | -51.50 | -36.95 | -65.94 | -44.77 | 92.12 | 95.92 | -259.11 | -165.79 | 3.41 | -- | 0.6526 | -- | 32.69 | -2.43 | -13.54 | -- | 16.49 | -- |
| Voyager Therapeutics Inc | 250.01m | 132.33m | 479.16m | 162.00 | 2.98 | 1.64 | 3.50 | 1.92 | 2.96 | 2.96 | 5.56 | 5.37 | 0.9792 | -- | 5.97 | 1,543,259.00 | 51.83 | 0.6378 | 70.85 | 0.8203 | -- | -- | 52.93 | 1.30 | -- | -- | 0.00 | 0.00 | 511.16 | 101.01 | 385.14 | -- | -5.43 | -- |
| Taysha Gene Therapies Inc | 15.45m | -111.57m | 480.64m | 52.00 | -- | 6.41 | -- | 31.11 | -1.37 | -1.37 | 0.1333 | 0.4008 | 0.1034 | -- | -- | 297,134.60 | -74.62 | -- | -111.87 | -- | -- | -- | -722.06 | -- | -- | -50.05 | 0.3529 | -- | 517.55 | -- | 32.80 | -- | -- | -- |
| Fulcrum Therapeutics Inc | 2.81m | -97.34m | 481.69m | 76.00 | -- | 2.04 | -- | 171.73 | -1.59 | -1.59 | 0.0458 | 3.80 | 0.0116 | -- | 1.68 | 36,907.89 | -40.19 | -50.55 | -42.88 | -55.91 | -- | -- | -3,470.05 | -1,189.10 | -- | -- | 0.00 | -- | -55.77 | -- | 11.41 | -- | -43.70 | -- |
| Arbutus Biopharma Corp | 18.14m | -72.85m | 488.27m | 73.00 | -- | 4.34 | -- | 26.92 | -0.4386 | -0.4386 | 0.1093 | 0.6241 | 0.1068 | -- | 11.60 | 248,506.80 | -42.88 | -52.62 | -51.22 | -58.11 | -- | -- | -401.57 | -537.81 | -- | -- | 0.00 | -- | -53.51 | 25.00 | -4.89 | -- | -2.40 | -- |
| Larimar Therapeutics Inc | 0.00 | -36.95m | 495.41m | 42.00 | -- | 4.17 | -- | -- | -0.8416 | -0.8416 | 0.00 | 1.86 | 0.00 | -- | -- | 0.00 | -33.24 | -42.22 | -36.56 | -47.14 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -4.51 | -- | 8.71 | -- |
Data as of May 03 2024. Currency figures normalised to Voyager Therapeutics Inc's reporting currency: US Dollar USD
32.99%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Armistice Capital LLCas of 31 Dec 2023 | 4.24m | 7.80% |
| EcoR1 Capital, LLCas of 31 Dec 2023 | 3.85m | 7.09% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 2.47m | 4.55% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 2.22m | 4.09% |
| Farallon Capital Management LLCas of 31 Dec 2023 | 1.29m | 2.38% |
| T. Rowe Price Associates, Inc. (Investment Management)as of 31 Dec 2023 | 976.29k | 1.80% |
| Dimensional Fund Advisors LPas of 31 Dec 2023 | 932.23k | 1.72% |
| Geode Capital Management LLCas of 31 Dec 2023 | 678.88k | 1.25% |
| AQR Capital Management LLCas of 31 Dec 2023 | 639.29k | 1.18% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 619.81k | 1.14% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
